DCISionRT
$5,300.00
Description:
DCISionRT is a risk assessment test for women diagnosed with DCIS (Ductal carcinoma in situ). DCISionRT evaluates a patient’s individual biology along with other risk factors to provide a personalized risk assessment. It predicts the risk of a future DCIS or invasive breast cancer recurrence in that same breast over the next 10 years. It also predicts the benefit from radiation therapy in reducing the risk of DCIS or invasive disease recurring.
What is DCIS?
Ductal carcinoma in situ (DCIS) is the presence of abnormal cells inside a milk duct in one or both breasts. DCIS is considered the earliest form of breast cancer and is sometimes referred to as Stage 0 (zero). DCIS is noninvasive, meaning it has not spread out from the milk duct and has a lower risk of progressing to invasive breast cancer.
Why would my physician use DCISionRT?
Your physician is gathering all of the available information to customize a treatment plan for you. Previously, most patients with a diagnosis of DCIS had typically been treated with surgery, radiation therapy and hormonal therapy. Today, DCISionRT provides additional information about your biological risk for the disease coming back and your likelihood of benefiting from radiation therapy. With this added information, your physician can recommend the best course of therapy for you, and together you can make a shared decision for treatment.
How does DCISionRT work?
DCISionRT looks at the biology of your DCIS tissue and assesses seven different biomarkers along the key biologic pathways responsible for the progression of breast cancer as well as four other risk factors. The test can be performed on the biopsy or the tissue removed during surgery. No additional procedures are required.
When should I have the DCISionRT test?
The DCISionRT test may be performed before or after breast conserving surgery. The tissue removed during surgery requires no additional procedure. Most patients have the test after surgery, but this depends on your physician’s preference and the goal of the treatment.
What information does DCISionRT provide?
The result of the test is called your DCISionRT Score. The Score is reported numerically on a scale from 0.0 to 10.0, and categorically as “Low” or “Elevated. The risk algorithm has been validated with information from thousands of patients with known outcomes and is used to calculate your individualized DCISionRT Score. Your DCISionRT Score correlates with your personal prognosis after treatment with surgery alone or with surgery and radiation therapy.
Name of Service Provider:
PreludeDx
About the Service Provider:
PreludeDx was founded with the goal of providing better decision-making tools to breast cancer patients and physicians. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing breast cancer tools that will impact a patient’s treatment decision. Our mission is to provide tools that improve patient outcomes in breast cancer and reduce the overall cost burden to the healthcare system.
Shipping Time:
3-5 days
Processing Time:
3-5 days